Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era-Reference-Cited by-同舟云学术

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era

Published:2011-10-17 Issue:11 Volume:118 Page:2944-2951
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kumar Anita,Vanderplas Ann,LaCasce Ann S.,Rodriguez Maria A.,Crosby Allison L.,Lepisto Eva,Czuczman Myron S.,Nademanee Auayporn,Niland Joyce,Gordon Leo I.,Millenson Michael,Zelenetz Andrew D.,Friedberg Jonathan W.,Abel Gregory A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma;van Besien;Blood,1998

2. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group;Bernstein;J Clin Oncol,2009

3. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model;Hollender;Ann Oncol,2002

4. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited;Bunn;Blood,1976

5. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL);Boehme;Blood,2009

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of the role of bone marrow biopsy and PET-CT in the evaluation of bone marrow involvement in adults newly diagnosed with DLBCL;Frontiers in Oncology;2024-03-21

2. Primary breast diffuse large B-cell lymphoma characterized by CNS relapse and successful hematopoietic stem cell transplantation salvage therapy;Journal of the Formosan Medical Association;2024-01

3. Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group;Cancer Medicine;2023-11-23

4. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study;Clinical Lymphoma Myeloma and Leukemia;2023-10

5. Consolidative breast radiotherapy and prophylactic high-dose methotrexate are important first-line treatments for primary breast diffuse large B-cell lymphoma patients treated with R-CHOP-like regimens;2023-01-04